Contaminating tumour cells in apheresis products have proved to influence the outcome of patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (APBSCT). The gene scanning of clonally rearranged VDJ segments of the heavy chain immunoglobulin gene (VDJH) is a reproducible and easy to perform technique that can be optimised for clinical laboratories. We used it to analyse the aphereses of 27 MM patients undergoing APBSCT with clonally detectable VDJH segments, and 14 of them yielded monoclonal peaks in at least one apheresis product. The presence of positive results was not related to any pretransplant characteristics, except the age at diagnosis (lower in patients with negative products, P ‫؍‬ 0.04). Moreover, a better pre-transplant response trended to associate with a negative result (P ‫؍‬ 0.069). Patients with clonally free products were more likely to obtain a better response to transplant (complete remission, 54% vs 28%; Ͼ90% reduction in the M-component, 93% vs 43% P ‫؍‬ 0.028). In addition, patients transplanted with polyclonal products had longer progression-free survival, (39 vs 19 months, P ‫؍‬ 0.037) and overall survival (81% vs 28% at 5 years, P ‫؍‬ 0.045) than those transplanted with monoclonal apheresis. In summary, the gene scanning of apheresis products is a useful and clinically relevant technique in MM transplanted patients. Bone Marrow Transplantation (2001) 28, 665-672.
multiple myeloma (MM) patients. [1] [2] [3] In this strategy, the contamination by residual tumour cells of the products used for the transplant has been an important concern. Currently, mobilised peripheral blood (PB) is preferred to bone marrow (BM) as the source for progenitor cells, not only because a more rapid engraftment is achieved with PB, but also because the number of contaminating tumour cells is lower in PB than in BM, particularly because the last is the natural location for malignant plasma cells. However, many authors, including our own group, have demonstrated that PB harvests can also contain a certain degree of tumour cell contamination. [4] [5] [6] [7] [8] Moreover, several studies have shown that this detection seems to have an adverse impact on the outcome after transplant, since it is related to the response and survival. [9] [10] [11] [12] [13] [14] [15] Most studies are based on the use of molecular marker analysis of clonally rearranged segments of the immunoglobulin (Ig) genes, but this strategy is associated with several pitfalls. For example, the use of ASO-PCR is technically complex and time-consuming. [16] [17] [18] In addition, the sensitivity is so high (10 Ϫ5
Ϫ6
) that it hampers the identification of risk categories since, with such sensitivity, virtually all autologous harvests show the presence of clonally rearranged cells. 16, 17, [19] [20] [21] The use of the fingerprinting technique is also time-consuming and difficult to interpret. 12, 22, 23 The heteroduplex PCR, previously used by our group, 9, 24 sometimes has difficulties in interpretation and sensitivity could be insufficient. The gene scanning of the VDJH-rearranged segments has emerged as a reliable and easy to perform technique, although it requires the use of an automated sequencer, providing positive results when applied to selective populations present in the infusion products. 15 In the present study, we report on the gene scanning technique for size fragment analysis of VDJH-rearranged products in order to detect clonally rearranged cells in the apheresis products of MM patients undergoing autologous peripheral blood stem cell transplantation (APBSCT). This strategy was able to detect residual clonally rearranged cells in 52% of patients, which resulted in the discrimination of a subgroup of patients in whom the response to high-dose therapy was worse, thus implying a shorter progression-free survival and overall survival after transplantation.
Bone Marrow Transplantation

Patients and methods
Patients
Thirty-six MM patients younger than 65 years, who received an APBSCT were prospectively included at the beginning of the study. Diagnosis of MM was made according to standard criteria. 25 In all of them, genomic DNA was extracted from diagnostic BM aspirates, but only 27 demonstrate VDJH clonal rearrangements detectable by gene scanning. In nine patients (25%) the PCR failed to amplify the monoclonal VDJH rearrangement due to wellknown reasons, 26 and were excluded from the study. The 27 patients displaying a valid and clonally rearranged VDJH segment were subsequently analysed. Twenty-three of them were transplanted within a protocol that included high-dose therapy as part of the front-line treatment. The remaining four patients were transplanted after relapsing and achieving a second response to salvage therapy. Table 1 displays the main clinical and biological characteristics of these 27 patients at the point of transplant.
Fifteen patients were mobilised with G-CSF alone (5-10 g/kg). The remaining 12 patients were mobilised using 2 g/m 2 of cyclophosphamide (CP) and G-CSF (10 g/kg).
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In these 12 cases, the collection was started when the peak of CD34 ϩ cells in PB was detected by flow cytometry as previously described. 28 The total number of aphereses was 74, with a median of two per patient (range ϭ 1-7). Five patients required extra mobilisation because of an insufficient number of cells in the first process. The conditioning regimen was melphalan 200 mg/m 2 in all cases, with dose schedule, care measures and discharge criteria according to the Spanish group for MM. 29 After transplantation, all patients were scheduled to receive maintenance treatment with interferon (3 ϫ 10 6 U/day, 3 days per week) and dexamethasone (40 mg/day, 4 days every 3 weeks).
Response criteria and outcome evaluation
The criteria for response evaluation following standard treatment and transplantation were those proposed by Bladé et al 30 considering the following types of response: complete response (CR), partial response (PR), minimal response (MR), no change (NC) and progressive disease (PD). PR was defined as (1) reduction of 50% or more of the M-component; (2) improvement in performance status by at least two grades according to the ECOG scale or up to grade 0; and (3) a decrease of over 50% in the measured cross-sectional area of plasmacytomas. Furthermore, the size and number of lytic bone lesions should not have increased, and correction of hypercalcemia (Ͻ11.0 mg/dl), anemia (Ͼ9 mg/dl), and hypoalbuminemia (Ͼ3.5 g/dl) should also have occurred. If no detectable M-component was present with less than 5% of BM PC, a CR was considered. In this case, a negative immunofixation, both in serum and urine, was required. Those patients who fulfilled all the above criteria, but without a 50% reduction of the M-component were considered to have a MR. When the criteria for PR or MR were not fulfilled, the case was considered a treatment failure, with a distinction between no change (NC) and progressive disease (PD). The best response status achieved in the 12 months after high-dose therapy was used for evaluation of the response to transplantation.
Overall survival (OS) was considered from the time of diagnosis until death. OS from transplantation was considered from the time of infusion of peripheral blood stem cells (PBSC) until death. Progression-free survival (PFS) was considered only for patients who achieved some kind of response (CR, PR, MR or NC) from the time point at which response was assessed after transplantation (day ϩ90) until progression or relapse.
DNA extraction, PCR amplification and gene scanning at diagnosis
Bone marrow aspirate specimens were obtained during the diagnostic procedures in all 36 MM patients. The number of plasma cells present in the sample was assessed by immunophenotyping at flow cytometry. 31 Standard proteinase K digestion, phenol-chloroform extraction and ethanol precipitation were used to isolate high molecular weight DNA. The quality of DNA was tested by PCR amplification of the ABL gene.
PCR analyses of the VDJ region of the Ig heavy chain gene (VDJH) were performed using approximately 500 ng of genomic DNA. The consensus primer pairs of the VH and JH segments, as well as the PCR conditions have been previously described, 26, 32 but in this case several changes were made: (1) the JH primer was 5Ј labelled with 6-FAM; (2) the Taq enzyme here used was TaqGold (Perkin Elmer, Foster City, CA, USA); (3) the first denaturation step was extended up to 15 min at 95°C; (4) the last extension step at 72°C was extended up to 45 min. Once the PCR was finished, the product was electrophoresed on agarose gels in order to check the PCR development and the quality of the PCR product.
Then, 2 l of the PCR product were mixed with 3 l of deionized formamide, 1 l of loading buffer (Perkin Elmer) and 0.5 l of the specific molecular marker (GeneScan 500 ROX; Perkin Elmer). This mixture was then warmed for 3 min at 95°C and loaded in a 5% polyacrylamide denaturing gel with urea placed in a 377 DNA automated sequencer (Applied Biosystems, Foster City, CA, USA). The electrophoresis was run for 2.5 h at 3000 V.
The quantification of the fluorescence and the calculation of the precise DNA fragment size was made with GeneScan software (Applied Biosystems). Gel preferences were multicomponent gel image, estimated maximum peak high of 1000 and confidence threshold of 50%. The analysis preferences included: (1) analysis range: full; (2) size call range: all sizes; (3) data processing: baseline, multicomponent and smooth options light; (4) size calling method: local southern; (5) peak detection with min peak half width: three patients; and (6) split peak correction: none. The remaining parameters were used by default.
A polyclonal pattern at gene scanning was considered when a group of peaks with a Gauss picture was obtained ( Figure 1a ). The monoclonal pattern showed a unique or double peak in the picture (Figure 1b Bone Marrow Transplantation was a prominent peak mixed with some other smaller, the criteria to consider the former as monoclonal was that the height of the monoclonal peak had to be at least double the others.
Sensitivity experiments
To determine the sensitivity of the gene scanning PCR technique, several dilution experiments were performed. DNA from samples displaying monoclonal products were serially diluted into two types of polyclonal DNA: (1) DNA extracted from polyclonal reactive tonsils containing more than 60% polyclonal B cells (counted by flow cytometry using the CD19 and / light chain expression), which were considered to be samples with a high polyclonal B cell background; and (2) DNA extracted from a pool of normal peripheral blood samples containing 7.3% of polyclonal B cells, which was considered to be a sample with a normal polyclonal B cell background. These two types of serial dilutions subsequently underwent the same gene scanning PCR analysis, and the sensitivity limit of the technique was considered to be the last dilution in which the monoclonal peak was distinguishable from the group of polyclonal peaks ( Figure 2 ).
Analysis of residual disease in the apheresis products
Seventy-four apheresis samples from 27 patients were analysed for the presence of clonally rearranged VDJH seg-
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Fluorescence intensity Figure 2 Example of sensitivity study with gene scanning analysis. Serial dilutions of a monoclonal sample within another sample with a high polyclonal B cell background. The sensitivity level reach a detection limit of 10
Ϫ4
. ments with the exact same size already detected at diagnosis. The procedure was the same as the one described above for diagnosis. All experiments were carried out at least twice, using positive and negative controls.
Statistical methods
To estimate the statistical significance of the differences observed in patients for continuous variables, the MannWhitney U and Kruskal-Wallis tests were employed, using the SPSS statistical software (SPSS, Chicago, IL, USA).
The chi-square test (Crosstabs, SPSS) was used for comparison of dichotomic variables between groups. Survival curves were plotted according to the method of Kaplan and Meier, and compared using the log-rank test (survival, SPSS).
Results
Patients' outcome
The transplant was successfully performed in all 27 cases and no transplant-related deaths were noted in this subset of patients. The mean hospitalisation period was 19 days. Twenty-five patients (93%) responded to transplant. Eleven of them (41%) achieved CR, with negative serum and urine IF, and 14 achieved PR. Only two patients did not respond to transplant: one patient did not achieve any reduction of the monoclonal component, but the disease remained stable, while the other one had demonstrated signs of progressive disease at time of evaluation. So far, 14 patients had progressed or relapsed, with a global median PFS from transplantation of 33 months. In the multivariate analysis, the main predictor for PFS was the response to transplant or, if excluded, response and performance status at the time of transplantation. Thus, the median PFS was 36 months for patients transplanted in CR or PR, while it was only 3 months for those with other status at transplant (stable or progressive disease).
Twelve patients have died due to disease progression, leading to a median OS of 48 months from transplant and 63 months from diagnosis. In the multivariate analysis, the main predictor was again the response to the high-dose therapy followed by the performance status at transplant, the last being the only independent predictor for OS when only pre-transplant characteristics were included in the analysis.
Dilution experiments and gene scanning analysis of apheresis products
The gene scanning PCR technique had a sensitivity of 10 Ϫ3 to 10
Ϫ4
. This range mainly depended on the number of polyclonal B cells present on the sample, which acted as confusing background. Thus, when the sample had a high polyclonal background (ie clonal samples mixed with reactive tonsils) the sensitivity was 10 Ϫ3 . By contrast, when the polyclonal background was lower (ie dilutions in DNA from peripheral blood samples) the sensitivity usually reached a level of 10 Ϫ 4 or even more. In all cases, the number of CD19 ϩ detected by flow cytometry cells was always Ͻ3%, a figure that indicates that the contamination by polyclonal B cells is even lower than that estimated in the dilution experiments with PB, where the sensitivity was 10
. Accordingly, we can assume a detection limit of at least 10 Ϫ4 in our investigation of apheresis products. Thus, the absence of monoclonal peaks would mean that the number of tumour cells in the aphereses is below one tumour cell per 10 000 normal cells.
Accordingly, of the 74 apheresis samples, 30 (41%) products displayed a monoclonal peak with the exact same size observed at diagnosis. In terms of patient numbers, this meant that 14 of 27 valid patients (52%) had at least one apheresis product with monoclonal VDJH segments. This would indicate the presence of contaminating neoplastic cells in the final product that was used for the infusion, in a level higher than one tumour cell per 10 000 cells. Table 2 displays the main clinical and biological characteristics of the group of patients transplanted with a gene scanning PCR-positive product compared with those receiving a negative product. There were no statistically significant differences in the disease characteristics, including performance status, bone disease, bone marrow plasma cell infiltration, renal function and haemoglobin, LDH, calcium or albumin levels, either at diagnosis or at transplant. There was an exception, which was the age at diagnosis, since patients who received negative products were younger than those transplanted with positive products. In addition, the gene scanning result showed a trend to be related with the response status at transplant, but differences did not reach statistical significance (P ϭ 0.069). Thus, while all 13 patients with negative apheresis products were in PR or CR, there were four patients transplanted with resistant disease in the group with positive aphereses ( Table 2 ). The mobilisation regimen (Ϯ chemotherapy) and the number of cycles received prior to the transplant (4 to 6) had no influence on the gene scanning result.
Correlation between gene scanning results and pretransplant characteristics
Post-transplant outcome and gene scanning results
Patients transplanted with apheresis products free of clonally rearranged cells were more likely to obtain CR after the transplant than those with contaminated aphereses. Thus, in the former group, the CR rate was 54%, while it was 28% in the group with positive apheresis (Table 2 ). In addition, the percentage of patients reaching у90% reduction in the M-component was 93% in the negative gene scanning group, but only 43% in the positive group (P ϭ 0.028).
So far, 10 out of the 14 patients (71%) transplanted with positive products had progressed or relapsed, while only four cases (31%) had progressed in the group with negative aphereses (P ϭ 0.035). This translated into a shorter PFS in the former group of patients compared with the second one (median PFS of 19 vs 39 months; 0% vs 44% free of progression at 5 years after transplant; log rank, P ϭ 0.037) (Table 2, Figure 3 ). These findings were consistent with the OS from transplant which was longer for patients trans-669 Table 2 Clinical and biological characteristics of the patients according to the detection of clonal cells in the apheresis products planted with negative gene scanning aphereses as compared to those transplanted with positive products (82% vs 15% at 5 years from transplant; log rank, P ϭ 0.037) ( Table  2 , Figure 4a ). In addition, contamination of apheresis also influenced OS from diagnosis, (81% vs 28% at 5 years for patients transplanted with negative or positive gene scanning apheresis, respectively; log rank, P ϭ 0.045) (Figure 4b ).
Discussion
The increasing use of high-dose therapy and APBSCT in MM therapy has introduced new concerns in the global management of these patients. One of them is the clinical significance of the presence of residual tumour cells in the products used for the transplant, since many studies have demonstrated that PB harvests can contain a variable degree of tumour contamination. [4] [5] [6] [7] [8] The first problem in resolving this concern was the technique to be applied in the investigation of the apheresis products. Morphological and cytogenetic techniques are not helpful, since their sensitivity (5%) is not enough. Flow cytometry has a good sensitivity for this purpose (10 Ϫ4 -10 Ϫ5 ), but few data are available and no assignment of clinical value has yet been possible. 31 So the majority of studies have been carried out with the help of molecular biology.
The use of qualitative ASO-PCR provides very high sensitivity, since it allows the detection of one single monoclonal cell among 10 5 -10 6 normal cells. [33] [34] [35] [36] However, the majority of these studies have demonstrated the persistence of minimal residual disease in the autologous aphereses of virtually all MM patients. This finding would predict an ultimate relapse of all patients, thus explaining the incurability of the disease with strategies including APBSCT, but is unable to predict differences in the patient outcome, which finally will be very variable.
The fingerprinting technique defined by others 12, 22, 23 is a technique with a lower sensitivity (10 Ϫ4 ). With this strategy, some groups have obtained clinically relevant results, 22, 36, 37 but the series studied have been short and long-term follow-up is still required. In addition, this technique can be time-consuming, requires the use of radioactive isotopes and can be associated with interpretation difficulties.
The heteroduplex PCR that we were using previously provided a good clinical correlation. 9 This technique has a sensitivity capable of detecting a single tumour cell among 10 3 -10 4 normal cells. 26, 32 In addition, it is simple, easy to perform and does not require expensive equipment. However, it sometimes has difficulties of interpretation and the sensitivity could seem insufficient in specific cases.
The gene scanning of the VDJH-rearranged segments has emerged as a new technique valid for these purposes. As a disadvantage, it requires the use of an automated sequencer, but it is easy to perform and the results seem to be reproducible, without many interpretation difficulties. It has already provided valuable clinical data in cell populations selected from the aphereses of MM patients undergoing APBSCT, 15 with an estimated sensitivity around 10 Ϫ3 -10
Ϫ4
. In this paper, the gene scanning of VDJH PCR-amplified segments confirmed a sensitivity of 10
, if the target sample has few polyclonal B cells, which is the normal picture in PBSC collections from MM patients. This sensitivity was enough to detect monoclonally rearranged cells in the products that were used for APBSCT in 14 out of 27 MM patients. These results are in accordance with other reports in the literature, 13, 21, 33, 34, 38, 39 although the frequency with which the myelomatous cells are detected in the aphereses varies among different reports. These differences can easily be explained according to the methodology employed by the different authors, since the range of sensitivities varies from 10 Ϫ3 to 10
Ϫ5
. Accordingly, those techniques with a sensitivity around 10 Ϫ3 -10
Ϫ4
(fingerprinting, 12, 22, 23 gene scanning, 15 and heteroduplex PCR 9 ) have reported similar results to the findings reported here. In addition, our findings demonstrate the existence of a correlation between the presence of contaminated apheresis and the outcome after transplant. Thus, the collection of PBSC products with low numbers of contaminating tumour cells (Ͻ10
) improves the response rate to transplant and achieves a better PFS and OS. Whether this impact is related to the tumour cells reinfused with the product or from tumour cells remaining in the patient after the high-dose therapy is not yet clear, since arguments favouring one or other option can be found in the literature or even within this paper itself.
These findings favour the utility of middle sensitive molecular techniques to investigate the MRD in PBSC harvests for MM autotransplantation. However, we cannot forget that more sensitive techniques (ASO-PCR) can detect MRD where these methods (fingerprinting, heteroduplex PCR or gene scanning) fail to find tumour cells. All these data suggest that using a technique combining a high sensitivity and quantitative approach (eg Real Time ASO-PCR), could be the key to definitively resolving the significance of MRD in the PBSC collections for autotransplantation, not only in MM, but also in other lymphoproliferative disorders.
In summary, our study shows that gene scanning is a valuable technique to detect clonally rearranged cells in the apheresis products for APBSCT in MM with prognostic implications.
